Eli Lilly and Company (LLY)
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according to a new report from Research and Markets, sales could swell to $104.9 billion by 2035.
Eli Lilly: Growth With Higher Margins
The Eli Lilly and Company investment thesis highlights a robust 2024 performance, driven by a strong pipeline and solid balance sheet, supporting a positive future outlook. The company's strong cash flow and financial health underpin its ability to capitalize on growth opportunities and weather potential risks. Future outlook remains optimistic, with strategic initiatives expected to drive sustained growth and shareholder value.
Lilly's weight-loss drug launch in India to energize rivals eyeing mega market
Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
5 Reasons It's Not Too Late to Buy Eli Lilly Stock
Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable healthcare company in the world, with a market cap of $730 billion.
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug regulator, it said on Thursday.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Are you reluctant to invest in stocks right now? That's understandable.
Billionaire Ken Griffin More Than Doubled His Stake In This Market-Beating Growth Stock
"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others apply to Ken Griffin, CEO and founder of Citadel.
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Is Eli Lilly Stock a Buy?
Like many pharma stocks, Eli Lilly (LLY -4.58%) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their medicines and will continue to order them through good times and more difficult times as well.
Why Eli Lilly Stock Flopped Today
Eli Lilly (LLY -4.58%) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of their value during the big market sell-off that day, and it wasn't only because of the general gloom.
Eli Lilly and Company (LLY) Management presents at Leerink 2025 Global Healthcare Conference (Transcript)
Eli Lilly and Company (NYSE:LLY ) Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - Head of IR Conference Call Participants Dave Risinger - Leerink Partners Dave Risinger All right. So, I think we should get started here.
